Artelo Biosciences completes 1-for-6 reverse split; cash falls to $2.1M with negative working capital

ARTELO BIOSCIENCES, INC.

1-for-6 reverse split effective June 13, 2025, reducing outstanding shares from 3,280,000 to ~546,667.
Authorized common shares cut from 50M to 8,333,333; preferred authorized reduced from 416,667 to 69,444.
Preliminary June 30, 2025 cash & equivalents ~$2.1M; working capital expected between -$1.2M and -$1.5M.
Company restates substantial doubt about going concern and continues to report recurring operating losses.
FY2024 net loss $9.8M (vs $9.3M in FY2023); accumulated deficit reached $50.1M at Dec 31, 2024.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.